91 related articles for article (PubMed ID: 17895500)
1. Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy.
Redman AR; Zheng J; Shamsi SA; Huo J; Kelly EJ; Ho RJ; Ritchie DM; Hon YY
Clin Appl Thromb Hemost; 2008 Jan; 14(1):29-37. PubMed ID: 17895500
[TBL] [Abstract][Full Text] [Related]
2. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
3. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
4. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Schalekamp T; Oosterhof M; van Meegen E; van Der Meer FJ; Conemans J; Hermans M; Meijerman I; de Boer A
Clin Pharmacol Ther; 2004 Nov; 76(5):409-17. PubMed ID: 15536456
[TBL] [Abstract][Full Text] [Related]
5. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
7. [Warfarin in the treatment of antiphospholipid syndrome].
Reshetniak TM; Kondrat'eva LV; Patrusheva NL; Patrushev LI
Ter Arkh; 2007; 79(5):47-54. PubMed ID: 17672075
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
9. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A
Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
[TBL] [Abstract][Full Text] [Related]
11. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
Wadelius M; Sörlin K; Wallerman O; Karlsson J; Yue QY; Magnusson PK; Wadelius C; Melhus H
Pharmacogenomics J; 2004; 4(1):40-8. PubMed ID: 14676821
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.
Mark L; Marki-Zay J; Fodor L; Hajdara I; Paragh G; Katona A
Kardiol Pol; 2006 Apr; 64(4):397-402; discussion 403-4. PubMed ID: 16699986
[TBL] [Abstract][Full Text] [Related]
13. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.
Moridani M; Fu L; Selby R; Yun F; Sukovic T; Wong B; Cole DE
Clin Biochem; 2006 Jun; 39(6):606-12. PubMed ID: 16630605
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
Caraco Y; Blotnick S; Muszkat M
Clin Pharmacol Ther; 2008 Mar; 83(3):460-70. PubMed ID: 17851566
[TBL] [Abstract][Full Text] [Related]
15. Genetic regulation of warfarin metabolism and response.
Daly AK; Aithal GP
Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
[TBL] [Abstract][Full Text] [Related]
16. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
[TBL] [Abstract][Full Text] [Related]
17. The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy.
Pchelina SN; Sirotkina OV; Taraskina AE; Vavilova TV; Shwarzman AL; Schwartz EI
Thromb Res; 2005; 115(3):199-203. PubMed ID: 15617742
[No Abstract] [Full Text] [Related]
18. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
Voora D; Eby C; Linder MW; Milligan PE; Bukaveckas BL; McLeod HL; Maloney W; Clohisy J; Burnett RS; Grosso L; Gatchel SK; Gage BF
Thromb Haemost; 2005 Apr; 93(4):700-5. PubMed ID: 15841315
[TBL] [Abstract][Full Text] [Related]
19. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9.
Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH
Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303
[TBL] [Abstract][Full Text] [Related]
20. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]